

The Manager-Listing National Stock Exchange of India Ltd Mumbai.

BSE Limited Mumbai.

Dear Sir.

11.02.2021





Independent Auditor's Review report on unaudited Quarterly and Year to date standalone financial results of Bal Pharma Limited pursuant to the Regulations 33 of SEBI (Listing obligations

practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NSVM & Associates
Chartered Accountants
Firm registration number: 010072S



| DAL FIFARMA LIMITED|
| CAN: IASTROKATORIFIC (1983)AS|
| Regd. (1)Gev. 31-32 Bonnar staft a foliatital Area, tacket Take, Bangalore 540-099
| Pac 850-41379260 | Fair, 640-21324857 | mail:secretarial gibilgharma C
| Standalone Financial Results For The Quarter and Period Finied 31 December 2020

(Ri in laški etcept EPS)

MNa		Stendalane					
	Particulars	Quarter Endrd		Nine Month ended		Year ended	
	NOTE OF TAXABLE PARTY.	31 December 2020	50 September 2019	31 December 2019	JJ December 191 9	31 December 2019	31 March 2020
		Constitut	Uprodited	l'newlited	Unsudited	L'unubited	audited
	facome			28/2			(
ı	Revenue from operations	6,269.55	6,427.59	4,299.71	17,902.38	13,690.35	17,067.28
2	Other income.	V1 U2	19 17	98 03	151.99	198.66	361.54



5. Based on our review conducted and procedures, performed, as, stated in parameter and a shown and



· .